Home » Stocks » EXEL

Exelixis, Inc. (EXEL)

Stock Price: $16.73 USD -0.21 (-1.24%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $16.65 -0.08 (-0.48%) Jul 23, 7:51 PM
Market Cap 5.24B
Revenue (ttm) 1.03B
Net Income (ttm) 64.77M
Shares Out 313.39M
EPS (ttm) 0.21
PE Ratio 81.61
Forward PE 50.51
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $16.73
Previous Close $16.94
Change ($) -0.21
Change (%) -1.24%
Day's Open 17.06
Day's Range 16.58 - 17.06
Day's Volume 1,097,313
52-Week Range 16.24 - 27.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

You don't need a lot of cash to begin or further your trek toward financial independence.

Other stocks mentioned: F, JUSHF
1 week ago - The Motley Fool

The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.

2 weeks ago - The Motley Fool

The biotech stock plunged after disappointing clinical results.

2 weeks ago - The Motley Fool

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the company's Executive Vice President, Scientific Strategy and Chief Scientific Officer, will pre...

2 weeks ago - Business Wire

You don't need to start with a fortune to make one on Wall Street.

Other stocks mentioned: CRLBF, RDFN
3 weeks ago - The Motley Fool

The stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company announced a negative ou...

3 weeks ago - Forbes

Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.

3 weeks ago - Zacks Investment Research

The company reported successful clinical trial results, but investors were still disappointed.

3 weeks ago - The Motley Fool

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche Holding AG's Tecen...

3 weeks ago - Benzinga

ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (...

3 weeks ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company's President, Product Development and Medical Affairs and Chief Medica...

1 month ago - Business Wire

You don't need a boatload of money to chart a path to financial freedom.

Other stocks mentioned: AZN, CVS
1 month ago - The Motley Fool

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

Other stocks mentioned: BMY
1 month ago - Zacks Investment Research

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

Other stocks mentioned: CPB, EXAS, SAVE, SRPT, ZTO
1 month ago - 24/7 Wall Street

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new p...

Other stocks mentioned: BMY
1 month ago - Business Wire

ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results from the phase 3 COSMIC-311 pivotal trial of cabozantinib (CA...

1 month ago - Business Wire

R&D spending is hurting earnings, but long-term investors shouldn't be worried.

1 month ago - The Motley Fool

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc exploratory analysis demonstrating that the efficacy benefits seen in the phase 3 CheckMate -9ER t...

1 month ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc analysis of the phase 3 CheckMate -9ER trial demonstrating that CABOMETYX® (cabozantinib) in combi...

1 month ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced promising phase 2 results for CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) in ...

1 month ago - Business Wire

One is growing revenue. And the other may soon launch its first product.

Other stocks mentioned: HGEN
1 month ago - The Motley Fool

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor confere...

1 month ago - Business Wire

Patient investors should make bank from this diverse collection of high-quality businesses.

Other stocks mentioned: EVER, GOOG, GOOGL, JUSHF
1 month ago - The Motley Fool

Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.

1 month ago - Zacks Investment Research

Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in patients with...

Other stocks mentioned: RHHBY
1 month ago - Benzinga

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of cabo...

2 months ago - Business Wire

Revenue growth will probably accelerate soon, but it might not be enough.

2 months ago - The Motley Fool

All three healthcare stocks could have solid growth prospects.

Other stocks mentioned: DMTK, TDOC
2 months ago - The Motley Fool

With the trading day about halfway over, the markets were somewhat mixed on Tuesday.

Other stocks mentioned: BNTX, FL
2 months ago - 24/7 Wall Street

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

2 months ago - Zacks Investment Research

You don't need a lot of cash to begin building wealth on Wall Street.

Other stocks mentioned: GRWG, SKLZ
2 months ago - The Motley Fool

Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 0.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year to $0.09, which beat th...

2 months ago - Benzinga

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an update on progress toward achieving key corporate objective...

2 months ago - Business Wire

ALAMEDA, Calif. & TOULOUSE, France--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the fut...

2 months ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will participate in fireside chats ...

2 months ago - Business Wire

They're generating revenue now -- and more is on the way.

Other stocks mentioned: BMY, VRTX
2 months ago - The Motley Fool

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p...

3 months ago - Business Wire

These fast-paced companies are on the leading edge of innovation.

Other stocks mentioned: JUSHF, ZM
3 months ago - The Motley Fool

The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.

3 months ago - Zacks Investment Research

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate t...

3 months ago - Business Wire

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.

3 months ago - Zacks Investment Research

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OP...

3 months ago - Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX®), nivolumab (OPDIVO®) an...

3 months ago - Business Wire

Searching for drug developers that are innovative, but come with relatively low risk? Look no further.

Other stocks mentioned: BNTX, ITCI
3 months ago - The Motley Fool

Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.

4 months ago - Zacks Investment Research

Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation study STELLAR-...

4 months ago - Benzinga

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b...

4 months ago - Business Wire

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to sup...

4 months ago - Business Wire

About EXEL

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, inclu... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2000
Stock Exchange
NASDAQ
Ticker Symbol
EXEL
Full Company Profile

Financial Performance

In 2020, Exelixis's revenue was $987.54 million, an increase of 2.04% compared to the previous year's $967.78 million. Earnings were $111.78 million, a decrease of -65.18%.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Exelixis stock is "Buy." The 12-month stock price forecast is 29.93, which is an increase of 78.90% from the latest price.

Price Target
$29.93
(78.90% upside)
Analyst Consensus: Buy